Vaccine potential for inactivated shigellae

Vaccine

Volumn 25, Issue 9, 2007, Pages 1581-1592

  Osorio, Manuel ^a   Bray, Mechelle D ^a   Walker, Richard I ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Dendritic cells; Enteric vaccines; Inactivated bacteria

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; SHIGELLA VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; BACTERIAL STRAIN; BAGG ALBINO MOUSE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG SYNTHESIS; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INCUBATION TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHIGELLA; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS; SURVIVAL RATE; VACCINATION;

ANIMALS; CYTOKINES; DENDRITIC CELLS; DYSENTERY, BACILLARY; ESCHERICHIA COLI PROTEINS; FIMBRIAE PROTEINS; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; SHIGELLA; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLA VACCINES; VACCINES, INACTIVATED;

EID: 33846196638     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.012     Document Type: Article

References (41)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Org 77 8 (1999) 651-666
2. Levine M.M., Gangarosa E.J., Barrow W.B., Weiss C.F., et al. Shigellosis in custodial institutions. V. Effect of intervention with streptomycin-dependent Shigella sonnei vaccine in an institution with endemic disease. Am J Epidemiol 104 1 (1976) 88-92
3. Sanchez J.L., Vasquez B., Begue R.E., Meza R., Castellares G., Cabezas C., et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 344 8932 (1994) 1273-1276
4. Jennison A.V., and Verma N.K. Shigella flexneri infection: pathogenesis and vaccine development. FEMS Microbiol Rev 28 1 (2004) 43-58
5. Formal S.B., Kent T.H., May H.C., Palmer A., Falkow S., and LaBrec E.H. Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine. J Bacteriol 92 1 (1966) 17-22
6. Mel D., Gangarosa E.J., Radovanovic M.L., Arsic B.L., and Litvinjenko S. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull World Health Org 45 4 (1971) 457-464
7. Coster T.S., Hoge C.W., VanDeVerg L.L., Hartman A.B., Oaks E.V., Venkatesan M.M., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67 7 (1999) 3437-3443
8. Kotloff K.L., Taylor D.N., Sztein M.B., Wasserman S.S., Losonsky G.A., Nataro J.P., et al. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun 70 4 (2002) 2016-2021
9. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 72 2 (2004) 923-930
10. Cohen D., Ashkenazi S., Green M.S., Gdalevich M., Robin G., Slepon R., et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349 9046 (1997) 155-159
11. Trach D.D., Clemens J.D., Ke N.T., Thuy H.T., Son N.D., Canh D.G., et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349 9047 (1997) 231-235
12. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Neogy P.K., Stanton B., et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 158 2 (1988) 372-377
13. Noriega F.R., Losonky G., Wang J.Y., Formal S.B., and Levine M.M. Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Infect Immun 64 1 (1996) 23-27
14. Kotloff K.L., Noriega F., Losonky FG.A., Sztein M.B., Wasserman S.S., Nataro J.P., et al. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun 64 11 (1996) 4542-4548
15. Venkatesan M.M., Hartman A.B., Newland J.W., Ivanova V.S., Hale T.L., McDonough M., et al. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. Infect Immun 70 6 (2002) 2950-2958
16. Grewal H.M., Hemming K.T., Vetvik H., Ahren C., Gjessing H.K., Sommerfelt H., et al. Measurement of specific IgA in faecal extracts and intestinal lavage fluid for monitoring of mucosal immune responses. J Immunol Methods 239 1-2 (2000) 53-62
17. Chakrabarti M.K., Bhattacharya J., Bhattacharya M.K., Nair G.B., Bhattacharya S.K., and Mahalanabis D. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta Paediatr 88 2 (1999) 161-165
18. Mukhopadhaya A., Mahalanabis D., Khanam J., and Chakrabarti M.K. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition. Vaccine 21 21-22 (2003) 3043-3050
19. Hartman A.B., Van De Verg L.L., and Venkatesan M.M. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines. Infect Immun 67 11 (1999) 5841-5847
20. Savarino S.J., Hall E.R., Bassily S., Wierzba T.F., Youssef F.G., Peruski Jr. L.F., et al. Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J 21 4 (2002) 322-330
21. Lucas M.E., Deen J.L., von Seidlein L., Wang X.Y., Ampuero J., Puri M., et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 352 8 (2005) 757-767
22. Reis e Sousa C., Sher A., and Kaye P. The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr Opin Immunol 11 4 (1999) 392-399
23. Rescigno M., Rotta G., Valzasina B., and Ricciardi-Castagnoli P. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2 4 (2001) 361-367
24. Palucka K., and Banchereau J. How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr Opin Immunol 14 4 (2002) 420-431
25. Edgeworth J.D., Spencer J., Phalipon A., Griffin G.E., and Sansonetti P.J. Cytotoxicity and interleukin-1beta processing following Shigella flexneri infection of human monocyte-derived dendritic cells. Eur J Immunol 32 5 (2002) 1464-1471
26. Sansonetti P.J., Phalipon A., Arondel J., Thirumalai K., Banerjee S., Akira S., et al. Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity 12 5 (2000) 581-590
27. Pulendran B., Kumar P., Cutler C.W., Mohamadzadeh M., Van Dyke T., and Banchereau J. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol 167 9 (2001) 5067-5076
28. Erfurth S.E., Grobner S., Kramer U., Gunst D.S., Soldanova I., Schaller M., et al. Yersinia enterocolitica induces apoptosis and inhibits surface molecule expression and cytokine production in murine dendritic cells. Infect Immun 72 12 (2004) 7045-7054
29. Guiney D.G., Hasegawa P., and Cole S.P. Helicobacter pylori preferentially induces interleukin 12 (IL-12) rather than IL-6 or IL-10 in human dendritic cells. Infect Immun 71 7 (2003) 4163-4166
30. Kranzer K., Eckhardt A., Aigner M., Knoll G., Deml L., Speth C., et al. Induction of maturation and cytokine release of human dendritic cells by Helicobacter pylori. Infect Immun 72 8 (2004) 4416-4423
31. Dreher D., Kok M., Cochand L., Kiama S.G., Gehr P., Pechere J.C., et al. Genetic background of attenuated Salmonella typhimurium has profound influence on infection and cytokine patterns in human dendritic cells. J Leukoc Biol 69 4 (2001) 583-589
32. Kotton C.N., and Hohmann E.L. Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun 72 10 (2004) 5535-5547
33. Cardenas L., Dasgupta U., and Clements J.D. Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers. Vaccine 12 9 (1994) 833-840
34. Tabrizi C.A., Walcher P., Mayr U.B., Stiedl T., Binder M., McGrath J., et al. Bacterial ghosts-biological particles as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 15 6 (2004) 530-537
35. Ranallo R.T., Fonseka C.P., Cassels F., Srinivasan J., and Venkatesan M.M. Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immun 73 1 (2005) 258-267
36. Barry E.M., Altboum Z., Losonsky G., and Levine M.M. Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine 21 5-6 (2003) 333-340
37. Haugan A., Thi Dao P.X., Glende N., Bakke H., Haugen I.L., Janakova L., et al. Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines. Vaccine 22 1 (2003) 7-14
38. Evans D.G., Evans Jr. D.G., Opekun A.R., and Graham D.Y. Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes. FEMS Microbiol Immunol 1 3 (1988) 117-125
39. Steinsland H., Valentiner-Branth P., Gjessing H.K., Aaby P., Molbak K., and Sommerfelt H. Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study. Lancet 362 9380 (2003) 286-291
40. Byrd W., Mog S.R., and Cassels F.J. Pathogenicity and immune response measured in mice following intranasal challenge with enterotoxigenic Escherichia coli strains H10407 and B7A. Infect Immun 71 1 (2003) 13-21
41. Noriega F.R., Liao F.M., Maneval D.R., Ren S., Formal S.B., and Levine M.M. Strategy for cross-protection among Shigella flexneri serotypes. Infect Immun 67 2 (1999) 782-788